Development and Use of a High-Throughput Screen to Identify Novel Modulators of the Corticotropin-Releasing Factor Binding Protein

­Development of a HT Screen to Identify Novel Modulators of the CRFBP   Overview A connection between the corticotropin signaling pathway and alcohol use disorder (AUD) has been shown previously. We developed a high throughput screen to ident…

­Development of an HT Screen to Identify Novel Modulators of the CRFBP
Overview:
A connection between the corticotropin signaling pathway and alcohol use disorder (AUD) has been shown previously. We developed a high throughput screen to identify small molecule modulators of this pathway as potential therapeutics for AUD.
 
Market Opportunity:
Currently available treatments for alcohol use disorder (AUD) include three pharmacotherapies approved by the Food and Drug Administration: disulfiram, naltrexone, and acamprosate. The clinical efficacy of these pharmacotherapies is marginal, and they all suffer from limiting contraindications. Thus, there is a critical need for more effective pharmacotherapies for AUD. 
 
Innovation and Meaningful Advantages:
Growing attention has been paid to the stress system—specifically, the signaling pathway of corticotropin-releasing factor (CRF)—as a pharmacological target for AUD, and the expression pattern of CRF binding protein (CRFBP) suggests a critical role in the modulation of the stress responses. Using a novel high throughput screen we developed, we were able to identify two negative allosteric modulators (NAMs) of CRFBP.  

Commercial Development: Current State and Next Steps:
We transferred this novel biological assay to our collaborator’s robotic facility and have screened >350,000 compounds. We have selected 2 allosteric modulators and tested them in an ex vivo preclinical alcohol model.

Collaboration Opportunity:
Our goal is to collaborate with biopharma partners/funders who can bring into play the developmental, translational, and financial resources needed to advance this technology into the commercial marketplace.

Principal Investigator:
Carolina Haass-Koffler PhD
Associate Professor of Psychiatry and Human Behavior
Brown University
Brown Tech ID #2579
carolina_haass-koffler@brown.edu 

IP Information:
2021-10-07; US 2021/0308107A1; published.

Publication:
Curley DE, et al., Corticotropin-releasing factor-binding protein as a novel target to restore brain homeostasis: lessons learned from alcohol use disorder research. Frontiers in Behavioral Neuroscience, section Motivation, and Reward (in press)
Haass-Koffler CL, et al., Defining the Role of Corticotropin-Releasing Factor Binding Protein in alcohol consumption, Translational Psychiatry  2016 PMID: 27845775, PMCID: PMC3434418

Website:

http://brown.technologypublisher.com/technology/45963


 Contact Information:

TTO Home Page: http://brown.technologypublisher.com

Name: Andrew Bond

Title: Director of Business Development - Life Sciences

Email: andrew_bond@brown.edu